Cancer Immunotherapy Review
151.2K views | +5 today
Follow
 
Scooped by Krishan Maggon
onto Cancer Immunotherapy Review
Scoop.it!

Macrophages Chase Neutrophils Away From Wounds to Resolve Inflammation - Newswise (press release)

Macrophages Chase Neutrophils Away From Wounds to Resolve Inflammation - Newswise (press release) | Cancer Immunotherapy Review | Scoop.it
Macrophages are best known for their Pac Man–like ability to gobble up cellular debris and pathogens in order to thwart infection.
Krishan Maggon 's insight:

Journal of Cell Biology, Vol. 207, No. 5; 13POST16190005; GM074827; HL007899; GM008692

more...
Cancer Immunotherapy Review
A magic life saving cure for advanced metastatic melanoma.  
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Ipilimumab (BMS) Review: A Cancer Breakthrough? - un knol de Krishan Maggon

Ipilimumab (BMS) Review: A Cancer Breakthrough? - un knol de Krishan Maggon | Cancer Immunotherapy Review | Scoop.it
FDA has approved Yervoy (ipilimumab, BMS) under REMS for the treatment of metastatic melanoma. The European expert panel CHMP...
more...
rosywills's comment, September 22, 2017 4:07 AM
Cancer Immunotherapy Market is expected to reach USD 119.39 Billion by 2021
Download Free Brochure @ http://bit.ly/2cHlrFH
Scooped by Krishan Maggon
Scoop.it!

Retrogenix CAR T Cell Specificity Screening | Cell Microarray Applications

Retrogenix CAR T Cell Specificity Screening | Cell Microarray Applications | Cancer Immunotherapy Review | Scoop.it
Our approaches for off-target screening of CAR T cells include screening the antigen recognition elements (scFv) and screening whole engineered CAR T cells...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Adoptive Cellular Therapy (ACT) With Allogeneic Activated Natural Killer (aNK) Cells in Patients With Advanced Merkel Cell Carcinoma (MCC): Preliminary Results of a Phase 2 Trial

Adoptive Cellular Therapy (ACT) With Allogeneic Activated Natural Killer (aNK) Cells in Patients With Advanced Merkel Cell Carcinoma (MCC): Preliminary Results of a Phase 2 Trial | Cancer Immunotherapy Review | Scoop.it
POSTERS Adoptive Cellular Therapy (ACT) With Allogeneic Activated Natural Killer (aNK) Cells in Patients With Advanced Merkel Cell Carcinoma (MCC): Preliminary Results of a Phase 2 Trial DOWNLOAD PDF POSTER
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Next generation of immune checkpoint therapy in cancer: new developments and challenges | Journal of Hematology & Oncology | Full Text

Next generation of immune checkpoint therapy in cancer: new developments and challenges | Journal of Hematology & Oncology | Full Text | Cancer Immunotherapy Review | Scoop.it
Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-tolerance and assist with immune response. In cancer, immune checkpoint pathways are often activated to inhibit the nascent anti-tumor immune response.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination | Journal for ImmunoTherapy of Cancer | Full Text

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination | Journal for ImmunoTherapy of Cancer | Full Text | Cancer Immunotherapy Review | Scoop.it
Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to enhance the priming and effector phases of the antitumor T-cell response rendering it an...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

CD22 CAR T-cell Therapy Effective After CD19 CAR Therapy Failure in Children With B-ALL

CD22 CAR T-cell Therapy Effective After CD19 CAR Therapy Failure in Children With B-ALL | Cancer Immunotherapy Review | Scoop.it
A CAR T-cell therapy specific for CD22 was safe and provided high response rates for pediatric patients with B-cell acute lymphoblastic leukemia who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Co‐expression of LAG3 and TIM3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients - Ma - - Clinical and Experimental Pharmacology and Physiology ...

Co‐expression of LAG3 and TIM3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients - Ma - - Clinical and Experimental Pharmacology and Physiology ... | Cancer Immunotherapy Review | Scoop.it
Macrophages incubated with LAG3+TIM3+ CD4+CD25+/hi T cells presented lower expression of MHC class II, CD80, CD86, and tumor necrosis factor alpha (TNFα) but higher expression of IL‐10, than macrophages incubated with LAG3‐TIM3‐ CD4+CD25+/hi T cells. Together, our investigations demonstrated that CRC patients presented an enrichment of circulating Treg cells, in which the LAG3+TIM3+ subset exhibited more potent expression of inhibitory molecules, and furthermore, the LAG3+TIM3+ Treg cells could suppress the proinflammatory activation of macrophages more potently than the LAG3‐TIM3‐ Treg cells.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer | Cancer Immunotherapy Review | Scoop.it
Loss of both alleles of the CDK12 gene defines a molecular subtype of metastatic castration-resistant
prostate cancer that is potentially targetable with immune checkpoint inhibitors.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Cancer: More targeted use of immunotherapy - SNF

Cancer: More targeted use of immunotherapy - SNF | Cancer Immunotherapy Review | Scoop.it
Doctors are increasingly fighting cancer by stimulating patients’ immune systems. SNSF-supported researchers have now discovered a method for predicting the likelihood of treatment success.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Relapsed/Refractory DLBCL Added to Approved CAR-T Cell Therapy Indications

Relapsed/Refractory DLBCL Added to Approved CAR-T Cell Therapy Indications | Cancer Immunotherapy Review | Scoop.it
Tisagenlecleucel is the only FDA-approved chimeric antigen receptor (CAR)-T cell therapy indicated for non-Hodgkin lymphomas (NHL) and B-cell acute lymphocytic leukemia (ALL)....
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A transcriptionally and functionally distinct PD-1 + CD8 + T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

A transcriptionally and functionally distinct PD-1 + CD8 + T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade | Cancer Immunotherapy Review | Scoop.it
We compared transcriptional, metabolic and functional signatures of intratumoral CD8+ T lymphocyte populations with high (PD-1T), intermediate (PD-1N) and no PD-1 expression (PD-1–) from non-small-cell lung cancer patients. PD-1T T cells showed a markedly different transcriptional and metabolic profile from PD-1N and PD-1– lymphocytes, as well as an intrinsically high capacity for tumor recognition. Furthermore, while PD-1T lymphocytes were impaired in classical effector cytokine production, they produced CXCL13, which mediates immune cell recruitment to tertiary lymphoid structures. Strikingly, the presence of PD-1T cells was strongly predictive for both response and survival in a small cohort of non-small-cell lung cancer patients treated with PD-1 blockade. The characterization of a distinct state of tumor-reactive, PD-1-bright lymphocytes in human cancer, which only partially resembles that seen in chronic infection, provides potential avenues for therapeutic intervention.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Responses

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T  Responses | Cancer Immunotherapy Review | Scoop.it
A chimeric antigen receptor system that can integrate signals from multiple antigens
and fine-tune T cell activation in a cell-type-specific manner holds promise for enhancing
the safety and specificity of CAR T cell therapies for cancer treatment.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Doctors Call Off Clinical Trial After Experimental Cancer Treatment Has Tragic Results

Doctors Call Off Clinical Trial After Experimental Cancer Treatment Has Tragic Results | Cancer Immunotherapy Review | Scoop.it
An experimental treatment to fight a rare type of cancer backfired, when the drug made the disease more aggressive.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Toxicity and management in CAR T-cell therapy

Toxicity and management in CAR T-cell therapy | Cancer Immunotherapy Review | Scoop.it
T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in hematologic malignancies with more modest responses when targeting solid ...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Asterias Biotherapeutics - AST-VAC immunotherapy platform

Asterias Biotherapeutics - AST-VAC immunotherapy platform | Cancer Immunotherapy Review | Scoop.it
Asterias Biotherapeutics, Inc. is a biotechnology company pioneering the field of regenerative medicine.

 

Its AST-VAC immunotherapy programs employ three common elements of dendritic cells, telomerase antigen, and the LAMP signal sequence to stimulate robust and specific immune responses to cancer cells.

 

Our platform includes two distinct approaches to create these vaccines: AST-VAC1, an autologous (patient-specific) vaccine based on cells sourced from the patient, and AST-VAC2, an allogeneic (non-patient specific) vaccine manufactured from our proprietary pluripotent stem cell platform. Both of these programs incorporate the three key elements of dendritic cells, telomerase and LAMP to stimulate immune responses to cancer cells. Additionally, both programs employ numerous improvements designed to improve both immune responses and manufacturability as compared to first generation dendritic cell therapies (Figure ):

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gilead Oncology CAR T-Cell Therapies Outlook Compelling - Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Oncology CAR T-Cell Therapies Outlook Compelling - Gilead Sciences, Inc. (NASDAQ:GILD) | Cancer Immunotherapy Review | Scoop.it
CAR T-Cell therapies are poised to cure diseases, a new exemplar for big pharma. Goldman Sachs asks: Is curing patients a sustainable business model?MIT predic...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) | Cancer Immunotherapy Review | Scoop.it
Abstract
CD19-specific chimeric antigen receptor (CAR) T cell therapy is highly effective against relapsed or refractory acute lymphoblastic leukemia (ALL), but is hindered by neurotoxicity. In 53 adult patients with ALL, we found a significant association of severe neurotoxicity with high pretreatment disease burden, higher peak CAR T cell expansion and early and higher elevations of proinflammatory cytokines in blood. Patients with severe neurotoxicity had evidence of blood-cerebrospinal fluid (CSF) barrier disruption correlating with neurotoxicity grade without association with CSF white blood cell count or CAR T-cell quantity in CSF. Proinflammatory cytokines were enriched in CSF during severe neurotoxicity with disproportionately high levels of IL6, IL8, MCP1 and IP10, suggesting central nervous system (CNS)-specific production. Seizures, seizure-like activity, myoclonus and neuroimaging characteristics suggested excitatory neurotoxicity, and we found elevated levels of endogenous excitatory agonists in CSF during neurotoxicity.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Abstracts —The International Cancer Immunotherapy Conference,

Abstracts —The International Cancer Immunotherapy Conference, | Cancer Immunotherapy Review | Scoop.it

The International Cancer Immunotherapy Conference, hosted by the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association of Cancer Research (AACR), is the reference meeting for immunotherapy...

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas

’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas | Cancer Immunotherapy Review | Scoop.it

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced positive long-term outcomes including durable remissions and encouraging safety findings from two Phase 2 studies of tab-cel™ (tabelecleucel), Atara’s most advanced off-the-shelf T-cell immunotherapy.  These single center, open-label studies enrolled patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) following allogeneic hematopoietic cell transplant (HCT) or solid organ transplant (SOT) who failed first-line therapy. Atara and its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) reported the Phase 2 results in a poster presentation at the 23rd Congress of the European Hematology Association (EHA), being held in Stockholm, Sweden, June 14-17, 2018.

 

Tab-cel™ demonstrated durable remissions and encouraging safety profile in patients with EBV+ PTLD who failed first line therapy

Median survival in SOT patients was 21.3 months and was not reached in the HCT population after 23.3 months

None of the responders (CR or PR) to tab-cel™ died of EBV+ PTLD; Two-year overall survival for these responding patients was 83% and 86% following HCT and SOT, respectively

Krishan Maggon 's insight:

FDA granted tab-cel™ Breakthrough Therapy Designation for EBV+ PTLD following allogeneic hematopoietic cell transplant (HCT) and in October 2016, tab-cel™ was accepted into the EMA Priority Medicines (PRIME) regulatory pathway for the same indication, providing enhanced regulatory support. Atara also received positive regulatory feedback from Health Canada in September 2017 supporting the submission of tab-cel™ for an expedited approval pathway. In addition, tab-cel™ has orphan status in the U.S. and EU.

Tab-cel™ is in Phase 3 clinical development for the treatment of EBV+ PTLD following an allogeneic hematopoietic cell transplant (MATCH study) or solid organ transplant (ALLELE study), and Atara is planning a Phase 1/2 study in NPC. Tab-cel™ is also available to eligible patients with EBV associated hematologic and solid tumors through an ongoing multicenter expanded access protocol clinical study, positive interim results of which were presented in December 2017 at the 59th American Society of Hematology (ASH) Annual Meeting.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors

T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors | Cancer Immunotherapy Review | Scoop.it
Purpose: Infused autologous tumor-infiltrating lymphocytes (TIL) and tumor-targeted chimeric antigen receptor (CAR) T cells typically surround malignant lesions or penetrate small tumor nodules but fail to penetrate large solid tumors, significantly compromising their antitumor impact.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Trends and advances in tumor immunology and lung cancer immunotherapy | Journal of Experimental & Clinical Cancer Research | Full Text

Trends and advances in tumor immunology and lung cancer immunotherapy | Journal of Experimental & Clinical Cancer Research | Full Text | Cancer Immunotherapy Review | Scoop.it
Among several types of tumor, lung cancer is considered one of the most fatal and still the main cause of cancer-related deaths. Although chemotherapeutic agents can improve survival and quality of life compared with symptomatic treatment, cancers usually still progress after chemotherapy and are often aggravated by serious side effects. In the last few years there has been a growing interest in immunotherapy for lung cancer based on promising preliminary results in achieving meaningful and durable treatments responses with minimal manageable toxicity. This article is divided into two parts, the first part discusses the role of human immune system in controlling and eradicating cancer and the mechanisms of immune response evasion by tumor. The second part reviews the recent progress made in immunotherapy for lung cancer with results from trials evaluating therapeutic vaccines in addition to immune checkpoint blockade, specifically cytotoxic T lymphocyte associated protein 4, programmed death receptor 1 pathway, using monoclonal antibodies.

Keywords
Lung cancerTumor immunologyImmunotherapyCancer vaccinesClinical trialsImmune checkpoint inhibitors
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC | NEJM

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC | NEJM | Cancer Immunotherapy Review | Scoop.it
The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status. (Funded by F. Hoffmann–La Roche/Genentech; IMpower150 ClinicalTrials.gov number, NCT02366143.)
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

CAR T-Cell Therapy: The Sticker Price Is Just for Openers

CAR T-Cell Therapy: The Sticker Price Is Just for Openers | Cancer Immunotherapy Review | Scoop.it
CMS has proposed a different way to handle payment for chimeric antigen receptor T-cell therapy, one that the medical and manufacturing community thinks is unworkable.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Chimeric Antigen Receptor T Cell (CAR T) Therapy

Chimeric Antigen Receptor T Cell (CAR T) Therapy | Cancer Immunotherapy Review | Scoop.it
Individualized CAR T therapy uses a patient’s own immune system to fight certain types of cancers. A patient’s T cells are extracted and reprogrammed outside of the body to recognize and fight cancer cells and other cells expressing a particular antigen.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies

A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies | Cancer Immunotherapy Review | Scoop.it
CAR T-cell therapies hold great promise for treating a range of malignancies but are however challenged by the complexity of their production and by the adverse events related to their activity. Here we report the development of the CubiCAR, a tri-functional CAR architecture that enables CAR T-cell detection, purification and on-demand depletion by the FDA-approved antibody Rituximab. This novel architecture has the potential to streamline the manufacturing of CAR T-cells, allow their tracking and improve their overall safety.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Rapid Progression of Adult T-Cell Leukemia–Lymphoma after PD-1 Inhibitor Therapy | NEJM

Rapid Progression of Adult T-Cell Leukemia–Lymphoma after PD-1 Inhibitor Therapy | NEJM | Cancer Immunotherapy Review | Scoop.it
Correspondence from The New England Journal of Medicine — Rapid Progression of Adult T-Cell Leukemia–Lymphoma after PD-1 Inhibitor Therapy

 

The consistent and rapid amplification of cancer in all 3 patients after a single dose of nivolumab in our trial provides support for the probable role of PD-1 functioning as a tumor suppressor in humans. It is unclear whether this finding is specific to ATLL. In a previous study, 4 of 23 patients with other forms of T-cell lymphoma had a response to nivolumab.4 It is noteworthy that the HTLV-1 basic zipper factor (HBZ) protein interferes with PD-1 signaling, which may have contributed to our findings.5Nevertheless, despite the recent recommendation to consider the use of PD-1 inhibitor therapy for ATLL,2 our clinical experience provides examples of cases in which this treatment may have led to rapid disease progression.

more...
No comment yet.